MetaVia Inc. (NASDAQ:MTVA – Free Report) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for MetaVia in a research report issued on Friday, March 21st. HC Wainwright analyst E. Arce forecasts that the company will post earnings of ($5.01) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share.
MetaVia Trading Up 1.9 %
Shares of MTVA stock opened at $1.58 on Monday. The company has a 50 day moving average of $1.69. MetaVia has a twelve month low of $1.29 and a twelve month high of $5.30.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Featured Stories
- Five stocks we like better than MetaVia
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Investing In Automotive Stocks
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Election Stocks: How Elections Affect the Stock Market
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
